The stock of Oxford Pharmascience Group Plc (LON:OXP) is a huge mover today! The stock increased 3.66% or GBX 0.08 on November 4, hitting GBX 2.12. About 2.37 million shares traded hands. Oxford Pharmascience Group Plc (LON:OXP) has declined 50.00% since April 7, 2016 and is downtrending. It has underperformed by 51.09% the S&P500.
The move comes after 7 months positive chart setup for the GBX 25.33M company. It was reported on Nov, 4 by Barchart.com. We have GBX 3.86 PT which if reached, will make LON:OXP worth GBX 20.77 million more.
Oxford Pharmascience Group Plc (LON:OXP) Ratings Coverage
Out of 2 analysts covering Oxford Pharmascience Group PLC (LON:OXP), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Oxford Pharmascience Group PLC has been the topic of 7 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The stock of Oxford Pharmascience Group Plc (LON:OXP) has “Corporate” rating given on Thursday, November 5 by N+1 Singer. N+1 Singer maintained the shares of OXP in a report on Tuesday, September 22 with “Corporate” rating. The company was maintained on Monday, January 25 by N+1 Singer. The firm has “Speculative Buy” rating given on Monday, March 7 by Beaufort Securities. The company was downgraded on Thursday, July 21 by Beaufort Securities. N+1 Singer maintained the stock with “Corporate” rating in Friday, July 31 report. The stock has “Corporate” rating given by N+1 Singer on Wednesday, August 12.
More news for Oxford Pharmascience Group Plc (LON:OXP) were recently published by: Uk.Finance.Yahoo.com, which released: “Oxford Pharmascience Group Plc (OXP.L)” on March 17, 2014. Fool.Co.Uk‘s article titled: “Should You Follow Neil Woodford And Buy GlaxoSmithKline plc, AstraZeneca plc …” and published on March 03, 2015 is yet another important article.
Oxford Pharmascience Group plc is a United Kingdom specialty pharmaceutical company. The company has a market cap of 25.33 million GBP. The Firm is engaged in re-developing medicines. It currently has negative earnings. The Firm engages in research and development activities based around its core technology platforms and focuses on commercializing the related products to pharmaceutical organizations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.